Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Nyxoah’s Sleep Apnea Device Receives FDA Breakthrough Tag

The FDA has granted Breakthrough Device Designation to Nyxoah SA (NASDAQ:NYXH) Genio bilateral hypoglossal nerve stimulation system. The…
byVandana Singh
September 14, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • The FDA has granted Breakthrough Device Designation to Nyxoah SA (NASDAQ:NYXH) Genio bilateral hypoglossal nerve stimulation system.
  • The system treats adult patients with moderate to severe Obstructive Sleep Apnea (OSA) and Complete Concentric Collapse (CCC) of the soft palate.
  • Genio system, Nyxoah’s lead solution, is patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy.
  • Related content: Benzinga’s Full FDA Calendar.
  • Price Action: NYXH stock is up 4.30% at $30.22 during the premarket session on the last check Tuesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts